Of the 397 patients with pancreatic cancer, 75 (18.9%) carried at least one cfDNA KRAS mutation at PDAC hotspot codons, a sensitivity close to that reported for the pilot series (17.5%). This evidence concerns the gene KRAS and familial pancreatic carcinoma.